Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $209M (up 31.4% year over year) with net income of $32M.
Q3 2025 key financials · XBRL
- Revenue
- $209M
- +31.4% YoY · +11.4% QoQ
- Net income
- $32M
- +237.5% YoY · +162.9% QoQ
- Operating margin
- 29.7%
- Gross margin
- 61.7%
- EPS (diluted)
- $0.84
- +211.1% YoY · +127.0% QoQ
Source: XBRL data from the COLLEGIUM PHARMACEUTICAL, INC (COLL) Q3 2025 10-Q on SEC EDGAR. USD.
COLLEGIUM PHARMACEUTICAL, INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New FDA opioid labeling requirements effective July 31, 2025 mandate safety changes including overdose info, increasing compliance costs and marketing challenges
- Most updated risk: $581.3M 2024 Term Loan and $241.5M 2029 Convertible Notes increase financial leverage and interest rate exposure via SOFR-linked variable rates
- Regulatory risk: September 2025 FDA intensified enforcement on direct-to-consumer advertising increases risk of sanctions for non-compliant product promotions
- Operational risk: sole supplier reliance for API manufacturing risks production disruptions impacting near-term product availability and costs
- Financial risk: 2024 Loan Agreement covenants limit additional debt, acquisitions, and risk triggering default with asset foreclosure potential
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other COLLEGIUM PHARMACEUTICAL, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.